These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Stoddart CA, Moreno ME, Linquist-Stepps VD, Bare C, Bogan MR, Gobbi A, Buckheit RW, Bedard J, Rando RF, McCune JM. Antimicrob Agents Chemother; 2000 Mar; 44(3):783-6. PubMed ID: 10681360 [Abstract] [Full Text] [Related]
4. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1. Kollmann TR, Pettoello-Mantovani M, Zhuang X, Kim A, Hachamovitch M, Smarnworawong P, Rubinstein A, Goldstein H. J Exp Med; 1994 Feb 01; 179(2):513-22. PubMed ID: 8294863 [Abstract] [Full Text] [Related]
6. thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. Pettoello-Mantovani M, Kollmann TR, Katopodis NF, Raker C, Kim A, Yurasov S, Wiltshire H, Goldstein H. J Infect Dis; 1998 Feb 01; 177(2):337-46. PubMed ID: 9466519 [Abstract] [Full Text] [Related]
10. Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms. Kovalev G, Duus K, Wang L, Lee R, Bonyhadi M, Ho D, McCune JM, Kaneshima H, Su L. J Immunol; 1999 Jun 15; 162(12):7555-62. PubMed ID: 10358212 [Abstract] [Full Text] [Related]
12. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. Satheesan S, Li H, Burnett JC, Takahashi M, Li S, Wu SX, Synold TW, Rossi JJ, Zhou J. J Virol; 2018 Apr 01; 92(7):. PubMed ID: 29343582 [Abstract] [Full Text] [Related]
13. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells. Wang EJ, Pettoello-Mantovani M, Anderson CM, Osiecki K, Moskowitz D, Goldstein H. J Infect Dis; 2002 Nov 15; 186(10):1412-21. PubMed ID: 12404156 [Abstract] [Full Text] [Related]
14. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Datema R, Charpiot B, Seifert J, Kaneshima H, McCune JM. Antimicrob Agents Chemother; 1996 Mar 15; 40(3):755-62. PubMed ID: 8851606 [Abstract] [Full Text] [Related]
15. Identification of HIV-1 determinants for replication in vivo. Su L, Kaneshima H, Bonyhadi ML, Lee R, Auten J, Wolf A, Du B, Rabin L, Hahn BH, Terwilliger E, Mccune JM. Virology; 1997 Jan 06; 227(1):45-52. PubMed ID: 9007057 [Abstract] [Full Text] [Related]
17. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model. Banda NK, Akkina RK, Terrell K, Shpall EJ, Tomczak J, Campain J, Claman H, Cagle L, Harrison GS. J Hematother; 1998 Aug 06; 7(4):319-31. PubMed ID: 9735863 [Abstract] [Full Text] [Related]
18. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. Kollmann TR, Kim A, Pettoello-Mantovani M, Hachamovitch M, Rubinstein A, Goldstein MM, Goldstein H. J Immunol; 1995 Jan 15; 154(2):907-21. PubMed ID: 7814892 [Abstract] [Full Text] [Related]
19. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses. Okuma K, Tanaka R, Ogura T, Ito M, Kumakura S, Yanaka M, Nishizawa M, Sugiura W, Yamamoto N, Tanaka Y. J Infect Dis; 2008 Jan 01; 197(1):134-41. PubMed ID: 18171296 [Abstract] [Full Text] [Related]
20. Activation of the signal transducer and activator of transcription 1 signaling pathway in thymocytes from HIV-1-infected human thymus. Miller ED, Smith JA, Lichtinger M, Wang L, Su L. AIDS; 2003 Jun 13; 17(9):1269-77. PubMed ID: 12799548 [Abstract] [Full Text] [Related] Page: [Next] [New Search]